Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline

Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best slow growth stocks to invest in. On November 21, Mizuho increased its price target for Gilead Sciences, Inc. (NASDAQ:GILD) from $131 to $140 while maintaining the stock’s Outperform rating. The firm cited a number of factors for the adjustment, including a longer exclusivity period for Biktarvy, with a US loss of exclusivity now anticipated in 2036 rather than the previous estimate of 2033 due to generic litigation settlements.

Yeztugo’s market potential was also emphasized by the company, which stated that the pre-exposure prophylaxis market might be “much larger than currently appreciated,” possibly reaching $15–20 billion.

Even so, Gilead Sciences, Inc. (NASDAQ:GILD) has been under pressure for certain other products. A Phase 3 trial for HR+/HER2-negative metastatic breast cancer revealed that Gilead Science’s cancer medication Trodelvy failed to fulfill its primary objective. The ASCENT-07 trial, which compared Trodelvy against chemotherapy, was unable to meet its main objective of progression-free survival.

Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the US, Europe, and internationally.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.